The medicinal chemistry of the P2 receptor family.
Guile
S D
SD
Department of Medicinal Chemistry, AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leicestershire, LE11 5RH, UK.
Ince
F
F
Ingall
A H
AH
Kindon
N D
ND
Meghani
P
P
Mortimore
M P
MP
D000241:Adenosine / Q000378:metabolism; D000244:Adenosine Diphosphate / Q000378:metabolism; D000249:Adenosine Monophosphate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy; D003001:Cloning, Molecular; D000077144:Clopidogrel; D003550:Cystic Fibrosis / Q000188:drug therapy; D006801:Humans; D009883:Ophthalmic Solutions / Q000627:therapeutic use; D011122:Polyphosphates; D018048:Receptors, Purinergic P2 / Q000737:chemistry / Q000378:metabolism; D013329:Structure-Activity Relationship; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014018:Tissue Distribution; D014500:Uracil Nucleotides
D009883:Ophthalmic Solutions; D011122:Polyphosphates; D018048:Receptors, Purinergic P2; D014500:Uracil Nucleotides; D000249:Adenosine Monophosphate; D000244:Adenosine Diphosphate; C117446:cangrelor; C403315:diquafosol; D000255:Adenosine Triphosphate; D000077144:Clopidogrel; D000241:Adenosine; D013988:Ticlopidine